Fluid Management in Dapagliflozin Therapy

Introduction to Dapagliflozin Mechanism

Dapagliflozin works by preventing glucose reabsorption in the kidneys, leading to increased urinary glucose excretion, which has implications for fluid balance, including osmotic diuresis, volume depletion risk, and dehydration potential, especially in elderly patients or those on concomitant diuretics 1, 2

Patients on dapagliflozin should drink at least 2-3 liters (8-12 cups) of water daily to prevent dehydration and maintain optimal fluid balance 1, 2
The American College of Cardiology recommends reducing diuretic dose when starting dapagliflozin to minimize volume depletion risk 2
Temporary discontinuation of dapagliflozin should be considered during severe illness or before surgical procedures to prevent dehydration and volume depletion 2

Patients should be monitored for signs of volume depletion, including dizziness, lightheadedness, weakness, and orthostatic hypotension, as well as kidney function and electrolyte balance 2
Patients should be educated on warning signs of dehydration, such as extreme thirst, dry mouth, fatigue, and dizziness, and instructed to increase fluid intake during illness, especially with fever, vomiting, or diarrhea 2
Educate the patient about signs/symptoms of ketoacidosis and implement a sick day protocol, and if the patient is on insulin, maintain at least a low dose to prevent ketosis 3
Counsel on genital hygiene to reduce the risk of genital mycotic infections, which occur in approximately 6% of patients on SGLT2 inhibitors compared to 1% on placebo 3

Dapagliflozin has shown benefits in reducing hospitalization and mortality in patients with heart failure, highlighting the importance of appropriate fluid management in these patients 2
The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) recommend the following dosing for dapagliflozin:
eGFR Dosing Recommendation
30-44 mL/min/1.73 m² (Stage 3b) 10 mg daily
25-29 mL/min/1.73 m² (Stage 4) Initiation not recommended
<25 mL/min/1.73 m² Initiation not recommended [3]
Dapagliflozin can be continued even if eGFR subsequently falls below the initiation threshold, providing kidney and cardiovascular benefits until dialysis is required 3, 1
The medication's glucose-lowering efficacy decreases as eGFR declines, but the kidney and cardiovascular benefits are preserved even at lower eGFR levels, making it valuable for cardiorenal protective effects beyond glycemic control 3

When initiating dapagliflozin, monitor for signs of volume depletion, especially if the patient is on diuretics, and consider proactive dose reduction of diuretics in high-risk patients 3
Be cautious with concomitant diuretics, as the combination may increase the risk of volume depletion 3
Failure to educate patients about sick day management and when to temporarily hold the medication can increase the risk of adverse events like ketoacidosis 3
Don't focus solely on glycemic control when evaluating efficacy in patients with reduced renal function, as the cardiovascular and renal benefits persist even when glucose-lowering effects diminish 3